These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7581482)

  • 1. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association.
    Caporaso N; DeBaun MR; Rothman N
    Pharmacogenetics; 1995; 5 Spec No():S129-34. PubMed ID: 7581482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
    Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
    J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
    Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
    Stücker I; Cosme J; Laurent P; Cenée S; Beaune P; Bignon J; Depierre A; Milleron B; Hémon D
    Carcinogenesis; 1995 Nov; 16(11):2759-64. PubMed ID: 7586196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 genotyping and the association with lung cancer susceptibility.
    Wolf CR; Smith CA; Bishop T; Forman D; Gough AC; Spurr NK
    Pharmacogenetics; 1994 Apr; 4(2):104-6. PubMed ID: 8081411
    [No Abstract]   [Full Text] [Related]  

  • 12. Debrisoquin oxidation genotype and susceptibility to lung cancer.
    Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
    Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of tobacco on lung cancer risk depends on CYP2D6 activity.
    Bouchardy C; Benhamou S; Dayer P
    Cancer Res; 1996 Jan; 56(2):251-3. PubMed ID: 8542575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Susceptibility to bronchial cancer: an example of genetic-environmental interaction].
    Benhamou S; Bonaïti-Pellié C
    Ann Biol Clin (Paris); 1995; 53(9):507-13. PubMed ID: 8830563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population.
    Kihara M; Kihara M; Noda K
    Carcinogenesis; 1995 Oct; 16(10):2331-6. PubMed ID: 7586131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of CYP2D6 and lung cancer risk.
    Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
    Ingelman-Sundberg M; Johansson I; Persson I; Yue QY; Dahl ML; Bertilsson L; Sjöqvist F
    Pharmacogenetics; 1992 Dec; 2(6):264-71. PubMed ID: 1306127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies].
    Vineis P; Landi MT; Caporaso N
    Med Lav; 1992; 83(6):557-75. PubMed ID: 1296137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.